iiinova — where your digital self keeps evolving

lucacocchineuro.bsky.social

@lucacocchineuro.bsky.social

19 followers 3 following 1 posts

Posts Replies Media

Reposted by @lucacocchineuro.bsky.social

bioRxiv Neuroscience @biorxiv-neursci.bsky.social · 29/09/2026

Evaluating the value and limits of null-models for Lesion Network Mapping www.biorxiv.org/content/10.64898/20…

011

Reposted by @lucacocchineuro.bsky.social

bioRxivpreprint @biorxivpreprint.bsky.social · 01/09/2026

Assessing specificity testing in Lesion Network Mapping www.biorxiv.org/content/10.64898/20…

001

Reposted by @lucacocchineuro.bsky.social

bioRxiv Neuroscience @biorxiv-neursci.bsky.social · 01/09/2026

Assessing specificity testing in Lesion Network Mapping www.biorxiv.org/content/10.64898/20…

011

Reposted by @lucacocchineuro.bsky.social

Dr Shane Huntington OAM @drshanerrr.bsky.social · 05/03/2026

NHMRC Investigator Grants out today. A devastating day for many. I have already received messages from some of the best researchers I know who have missed out. The senior levels had a cutoff of 5.93 (females), 6.2 (males) - according to my sources. The impact will be wide spread.

1127

Reposted by @lucacocchineuro.bsky.social

Carina Forster @carinafo.bsky.social · 30/03/2025

#OHBM2025Brisbane #BrainConnectivity If you visit the land down under for OHBM25, join us for the satellite Brain Connectivity Workshop on beautiful Minjerribah (North Stradbroke Island). Register now to secure the early bird discount. qimrberghofer.eventsair.com/brain-connec...

036

lucacocchineuro.bsky.social @lucacocchineuro.bsky.social · 14/04/2025

New: karger.com/pps/article/... . fMRI-personalised TMS for MDD: response (52%)/remission (33%), superior to open-label standard rTMS (31%/23%). RCT-acceptable (74%/53%). Response decreasing with co-morbidity (44%/ 24%) and bipolar depression or co-occurring neurological conditions (37% / 25%).

031